Journal: EMBO Molecular Medicine

Article Title: X-linked myopathy with excessive autophagy: characterization and therapy testing in a zebrafish model

doi: 10.1038/s44321-025-00204-8

Figure Lengend Snippet: ( A ) Results from birefringence assessment of vma21 Δ14ins21 heterozygote in-cross matings with zebrafish larvae incubated in autophagy library drug compounds. Dorsal muscle birefringence assessments of the drug-treated vma21 Δ14ins21/Δ14ins21 homozygote zebrafish larvae offspring. Zebrafish were scored as dead (gray bars; no detectable heartbeat), affected (red bars; showing at least one area of poor birefringence), or unaffected (green bars; no birefringence). Dashed lines shown at 25%, 18%, and 12.5% target range for lead compound advancement. ( B ) Long-term survivability assessment of eight autophagy antagonists tested in the vma21 Δ14ins21/Δ14ins21 homozygote mutant zebrafish advanced from the first pass short-term screen, LY294002 (positive control), and vehicle and untreated (negative controls). ( C ) Touch-evoke response measured with % of fish shown and groupings of high responders (green bars), medium responders (yellow bars), and low/non-responders (red bars). Compounds are administered into vma21 Δ14ins21/Δ14ins21 homozygote mutant zebrafish at 1 dpf and drug water was changed every other day over a 21-day time period. The compounds include: ROC-325, GSK2578215A, DC661, MRT68921 HCl, Lucanthone, CZC-25146, GNE7915, edaravone, and LY294002 administered at 2.5 µM. Vehicle and untreated controls are also shown. One hundred ( n = 100) vma21 Δ14ins21/Δ14ins21 mutant fish were assessed over 3 independent trials. Compounds were later validated in the vma21D1/D1 mutant zebrafish. ( D ) Percentage of larvae with fluorescence in the gallbladder at 6 dpf following feeding with BODIPY as a measure of bile acid flux. n = 10–22/group. Data represented as mean ± SEM. Not significant (ns; P > 0.05, Fisher’s exact test). .

Article Snippet: The PI3K inhibitor LY294002 (Selleck Chemicals; Cat# S1105) was used as a positive control for all experiments along with edaravone (MCI-186; Selleck Chemicals; Cat# S1326) in later drug evaluation experiments.

Techniques: Incubation, Mutagenesis, Positive Control, Fluorescence

Journal: EMBO Molecular Medicine

Article Title: X-linked myopathy with excessive autophagy: characterization and therapy testing in a zebrafish model

doi: 10.1038/s44321-025-00204-8

Figure Lengend Snippet: Western immunoblots of drug-treated zebrafish as well as densitometry quantification showing the expression in drug-treated vma21 Δ 14ins21/ Δ 14ins21 mutant homozygote mutant fish cohorts for ( A , B ) Lc3-I/II, ( C , D ) p62 (Sqstm1), and ( E , F ) Becn1 (Atg6) normalized to β-actin (Actb) loading controls. Nine drug compounds (Edaravone, LY294002, GNE7915, CZC-25146, Lucanthone, MRT68921 HCl, DC661, GSK2578215A, ROC-325) along with untreated and vehicle controls were evaluated. One-way ANOVA are shown with P values indicated as the following: * P < 0.05; ** P < 0.01; *** P < 0.005; **** P < 0.001. Each western blot had a total of three biological replicates. For each sample, n = 30 zebrafish were utilized. Data represented as mean ± SEM. .

Article Snippet: The PI3K inhibitor LY294002 (Selleck Chemicals; Cat# S1105) was used as a positive control for all experiments along with edaravone (MCI-186; Selleck Chemicals; Cat# S1326) in later drug evaluation experiments.

Techniques: Western Blot, Expressing, Mutagenesis

Journal: EMBO Molecular Medicine

Article Title: X-linked myopathy with excessive autophagy: characterization and therapy testing in a zebrafish model

doi: 10.1038/s44321-025-00204-8

Figure Lengend Snippet: Reagents and tools table

Article Snippet: The PI3K inhibitor LY294002 (Selleck Chemicals; Cat# S1105) was used as a positive control for all experiments along with edaravone (MCI-186; Selleck Chemicals; Cat# S1326) in later drug evaluation experiments.

Techniques: Recombinant, Sequencing, Lysis, Bicinchoninic Acid Protein Assay, Western Blot, Drug discovery, Plasmid Preparation, Software, Transmission Assay, Microscopy

Journal: Journal of Radiation Research

Article Title: Chemical repair activity of free radical scavenger edaravone: reduction reactions with dGMP hydroxyl radical adducts and suppression of base lesions and AP sites on irradiated plasmid DNA

doi: 10.1093/jrr/rru079

Figure Lengend Snippet: Chemical structure of edaravone in water.

Article Snippet: Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), Tris, boric acid, ethylenediaminetetraacetic acid (EDTA)·2Na·2H 2 O, sodium hydrate (NaOH), 1% bromophenol blue, Orange G, NaH 2 PO 4 and Na 2 HPO 4 were purchased from Wako Pure Chemical Industries, Ltd (Osaka, Japan).

Techniques:

Journal: Journal of Radiation Research

Article Title: Chemical repair activity of free radical scavenger edaravone: reduction reactions with dGMP hydroxyl radical adducts and suppression of base lesions and AP sites on irradiated plasmid DNA

doi: 10.1093/jrr/rru079

Figure Lengend Snippet: Transient absorption spectra obtained 1 μs (closed circles) and 80 μs (open squares) after irradiation by pulse radiolysis of a N 2 O-saturated aqueous solution containing 2 × 10 −3 mol dm −3 dGMP, 1.0 × 10 −4 mol dm −3 edaravone, and 2.0 × 10 −2 mol dm −3 phosphate buffer at pH 6.9. Inset: the transient spectrum obtained 80 μs after irradiation by pulse radiolysis of a N 2 O-saturated aqueous solution containing 2 × 10 −3 mol dm −3 dGMP.

Article Snippet: Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), Tris, boric acid, ethylenediaminetetraacetic acid (EDTA)·2Na·2H 2 O, sodium hydrate (NaOH), 1% bromophenol blue, Orange G, NaH 2 PO 4 and Na 2 HPO 4 were purchased from Wako Pure Chemical Industries, Ltd (Osaka, Japan).

Techniques: Irradiation

Journal: Journal of Radiation Research

Article Title: Chemical repair activity of free radical scavenger edaravone: reduction reactions with dGMP hydroxyl radical adducts and suppression of base lesions and AP sites on irradiated plasmid DNA

doi: 10.1093/jrr/rru079

Figure Lengend Snippet: Time profiles of absorbance at ( a ) 320, ( b ) 350 and ( c ) 600 nm of the solutions containing several concentrations of edaravone and 2 × 10 −3 mol dm −3 dGMP at pH 6.9.

Article Snippet: Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), Tris, boric acid, ethylenediaminetetraacetic acid (EDTA)·2Na·2H 2 O, sodium hydrate (NaOH), 1% bromophenol blue, Orange G, NaH 2 PO 4 and Na 2 HPO 4 were purchased from Wako Pure Chemical Industries, Ltd (Osaka, Japan).

Techniques:

Journal: Journal of Radiation Research

Article Title: Chemical repair activity of free radical scavenger edaravone: reduction reactions with dGMP hydroxyl radical adducts and suppression of base lesions and AP sites on irradiated plasmid DNA

doi: 10.1093/jrr/rru079

Figure Lengend Snippet: Dose–response curves of the remaining fraction of closed circular plasmid DNA in 2.0 × 10 −2 mol dm −3 phosphate buffer (pH 7) aqueous solution of 1.0 × 10 −2 g dm −3 pUC18 plasmid DNA with 100 μmol dm −3 edaravone (open symbols). The results of our previous study in DNA solution without the addition of antioxidants are also plotted (closed symbols) . Circles: DNA directly analyzed without any chemical treatments after irradiation; diamonds: DNA incubated with Nth treatment after irradiation; squares: DNA incubated without Nth treatment after irradiation.

Article Snippet: Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), Tris, boric acid, ethylenediaminetetraacetic acid (EDTA)·2Na·2H 2 O, sodium hydrate (NaOH), 1% bromophenol blue, Orange G, NaH 2 PO 4 and Na 2 HPO 4 were purchased from Wako Pure Chemical Industries, Ltd (Osaka, Japan).

Techniques: Plasmid Preparation, Irradiation, Incubation

Journal: Journal of Radiation Research

Article Title: Chemical repair activity of free radical scavenger edaravone: reduction reactions with dGMP hydroxyl radical adducts and suppression of base lesions and AP sites on irradiated plasmid DNA

doi: 10.1093/jrr/rru079

Figure Lengend Snippet: Ratios of the chemical yields of prompt SSBs and of Nth-, Fpg- and Nfo-sensitive sites obtained in the presence of edaravone at several concentrations ( G ) to the yields obtained without edaravone ( G 0 ).

Article Snippet: Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), Tris, boric acid, ethylenediaminetetraacetic acid (EDTA)·2Na·2H 2 O, sodium hydrate (NaOH), 1% bromophenol blue, Orange G, NaH 2 PO 4 and Na 2 HPO 4 were purchased from Wako Pure Chemical Industries, Ltd (Osaka, Japan).

Techniques:

Journal: PLoS ONE

Article Title: Edaravone Protect against Retinal Damage in Streptozotocin-Induced Diabetic Mice

doi: 10.1371/journal.pone.0099219

Figure Lengend Snippet: (A) Average contrast implicit time of P50 response in the three groups. (B) Average contrast implicit time of N95 response in the three groups. (C) Average contrast amplitude of P50 response in the three groups. (D) Average contrast amplitude of N95 response in the three groups. The nonparametric Kruskal-Wallis test followed by the Mann-Whitney test was used for multiple-group comparison. Values are the means ± SD of three independent experiments.*P<0.05, ***P<0.001 vs. Normal, # P<0.05 vs. Edaravone.

Article Snippet: Edaravone (Mitsubishi Pharma Corporation, Tokyo, Japan) was dissolved in dimethyl sulfoxide (DMSO) and was diluted with physiologic saline to a concentration of 3 mg/mL.

Techniques: MANN-WHITNEY, Comparison

Journal: PLoS ONE

Article Title: Edaravone Protect against Retinal Damage in Streptozotocin-Induced Diabetic Mice

doi: 10.1371/journal.pone.0099219

Figure Lengend Snippet: Quantification of TUNEL (+) cells showed significantly decreased TUNEL (+) cells/mm 2 with treatment of edaravone, compared with the streptozotocin-treated group. Data are expressed as the mean±SD. *P<0.05, ***P<0.001 vs. Normal, # P<0.05 vs. Edaravone. Original magnification: ×10; scale bar, 100 µm.

Article Snippet: Edaravone (Mitsubishi Pharma Corporation, Tokyo, Japan) was dissolved in dimethyl sulfoxide (DMSO) and was diluted with physiologic saline to a concentration of 3 mg/mL.

Techniques: TUNEL Assay

Journal: PLoS ONE

Article Title: Edaravone Protect against Retinal Damage in Streptozotocin-Induced Diabetic Mice

doi: 10.1371/journal.pone.0099219

Figure Lengend Snippet: (A) Data are expressed as percentage change in phosphorylated ERK1/2 (p-ERK1/2) over total ERK1/2 (t-ERK1/2) (B) The histogram represents the mean band intensity of BDNF adjusted to the intensity of β-actin in the same sample. (C) The ratio of active caspase-3 (17 kDa) and pro-caspase-3 (37 kDa) was calculated in control and diabetic mice maintained with and without Edaravone treatment. Measurements were made in duplicate in six to eight mice in each group. Western blots are representative of three different experiments. Results are expressed as mean±SD. Values obtained from Normal group are considered as 100%. *P<0.05, ***P<0.001 vs. Normal, # P<0.05 vs. Edaravone.

Article Snippet: Edaravone (Mitsubishi Pharma Corporation, Tokyo, Japan) was dissolved in dimethyl sulfoxide (DMSO) and was diluted with physiologic saline to a concentration of 3 mg/mL.

Techniques: Control, Western Blot

Journal: PLoS ONE

Article Title: Edaravone Protect against Retinal Damage in Streptozotocin-Induced Diabetic Mice

doi: 10.1371/journal.pone.0099219

Figure Lengend Snippet: Freshly prepared retinal homogenates were incubated with DCHFDA (5 µM) for 15 min. An equal amount of protein was used to quantitate 2′,7′-dichlorofluorescein fluorescence. Data are expressed as percent normal control and mean±SD from retina in each group. *P<0.05, ***P<0.001 vs. Normal, # P<0.05 vs. Edaravone.

Article Snippet: Edaravone (Mitsubishi Pharma Corporation, Tokyo, Japan) was dissolved in dimethyl sulfoxide (DMSO) and was diluted with physiologic saline to a concentration of 3 mg/mL.

Techniques: Incubation, Fluorescence, Control

Journal: Drug Design, Development and Therapy

Article Title: Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor

doi: 10.2147/DDDT.S144807

Figure Lengend Snippet: Lipid peroxidation, antioxidant enzyme activity, and myocardial hypertrophy among the different groups. Notes: ( A ) MDA content and SOD activity in myocardial tissue were determined using commercial kits. HW/BW (mg/g) was calculated by weight. ( B ) MSA in series was measured morphometrically at a HPF (original magnification: ×200; scale bars: 100 μm). Sham: rats underwent the same surgical procedure without banding the aorta; TAC: the ascending aorta was bended for 8 weeks; TAC plus edaravone (Edara): rats received an intraperitoneal injection of edaravone at a dose of 10 mg/kg/day for 8 weeks after TAC; TAC plus telmisartan (Telmi): telmisartan was administered via gastric gavage at a dose of 10 mg/kg/day for 8 weeks after TAC. Values are mean ± SEM (n=6/group). * p <0.05 TAC versus Sham; # p <0.05 Edara or Telmi versus TAC. Abbreviations: MDA, malonaldehyde; SOD, superoxide dismutase; HW/BW, heart to body weight ratio; MSA, myocyte sectional area; HPF, high-powered field; TAC, transverse aortic constriction; SEM, standard error of means.

Article Snippet: The rats were randomly divided into four groups (n=6 in each group) after surgery: 1) sham operation (Sham) – rats underwent the same surgical procedure without banding the aorta; 2) TAC – rats were subjected to TAC for 8 weeks; 3) TAC plus edaravone (Edara; Boda Pharmaceutical Co, Ltd, Jilin, China) – rats received an intraperitoneal injection of edaravone at a dose of 10 mg/kg/day after TAC; 4) TAC plus telmisartan (Telmi) – rats were administered telmisartan (Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA) via gastric gavage at a dose of 10 mg/kg/day after TAC.

Techniques: Activity Assay, Injection